|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy.
|
31815785 |
2020 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two classes of antidiabetic agents used in the management of diabetes based on incretin hormones.
|
31837333 |
2020 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Glucagon-like peptide 1 receptor agonists improve cardiovascular outcomes in patients with diabetes.
|
31620788 |
2020 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
GLP-1 therapy is effective concerning weight loss in overweight patients and is more often used in females and patients with shorter diabetes duration.
|
31471633 |
2020 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
The discovery of incretins (including GLP-1 and GIP) provides a novel therapy for the treatment of diabetes.
|
31785994 |
2020 |
|
Diabetes Mellitus
|
0.300 |
AlteredExpression
|
group |
BEFREE |
These studies highlight the clear, and persistent, metabolic advantages of sustained activation of GLP-1 receptors, alongside concurrent activation of related GIP and xenin cell signalling pathways, in diabetes.
|
31756326 |
2020 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Modulation of platelet function by diabetes agents in addition to their hypoglycemic effects would contribute to cardiovascular protection Newly introduced antidiabetic drugs of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors may have anti-platelet effects, and in the case of SGLT2i and GLP-1RA may contribute to their proven cardiovascular benefit that has been shown clinically.
|
31612835 |
2020 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Also, attention was diverted away from GIP by the successful development of glucagon-like peptide-1 (GLP-1) receptor agonists, and a therapeutic strategy for GIP became uncertain when evidence emerged that both inhibition and enhancement of GIP action could prevent or reverse obese non-insulin dependent forms of diabetes in rodents.
|
31756366 |
2020 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
The glucagon-like peptide-1 receptor (GLP-1R) agonist - liraglutide (LIR) - is an insulin secretagogue for the treatment of diabetes and has been proven to have therapeutic potential in the treatment of COPD.
|
30349227 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
The effect of the treatment with glucagon-like peptide (GLP)-1 receptor agonists on gastric emptying in patients with diabetes with and without gastroparesis is analysed.
|
30690693 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Indeed, bodyweight reduction by GIPR/GLP-1R dual agonists was greater than GLP-1R single agonists in individuals with type 2 diabetes.
|
30637966 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Data on weight, insulin, GLP-1 RA and SGLT-2i use were collected retrospectively (12 years) and prospectively (8 years) from patients included in the DIAbetes and LifEstyle Cohort Twente-1 (DIALECT-1, n = 450, age 63 ± 9 years, 58% men, diabetes duration [7-18] years).
|
31216324 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
GLP-1 agonists are a candidate treatment in CF-related diabetes.
|
30259623 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Compounds 1 and 2 displayed high affinities to target proteins GLP-1R (diabetes) and eEF2K (cancer) with K<sub>d</sub> values of 0.0285 μM, 0.0162 μM for GLP-1R and 0.118 μM, 0.0746 μM for eEF2K, respectively.
|
30990084 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Whether dual GLP-1R/GCR agonism represents a treatment method that is superior to pure GLP-1R agonists for obesity and diabetes treatment remains to be confirmed.
|
30091218 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Due to uncomfortable injection regimens of peptidic agonists of glucagon-like peptide-1 receptor (GLP-1R), orally available nonpeptide positive allosteric modulators (PAMs) of GLP-1Rs are foreseen as the possible future mainstream therapy for type 2 diabetes.
|
30609277 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
GLP-1 agonists such as exenatide and liraglutide are novel drugs for the treatment of diabetes and obesity.
|
30906473 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
GLP-1, a peptide hormone secreted from the gut stimulating insulin and suppressing glucagon secretion was identified as a parent compound for novel treatments of diabetes, but was degraded (dipeptidyl peptidase-4) eliminated (mainly kidneys) too fast (half-life 1-2 min) to be useful as a therapeutic agent.
|
31600725 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
|
31064213 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Glucagon-like peptide-1 is a peptide of incretin family which is used in the management of diabetes as glucagon-like peptide-1 receptor agonist (GLP-1RA).
|
31425698 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
The Glp-1 analog, liraglutide (Lir), has been shown to reduce infarct size and improve cardiac function after myocardial ischemia in rodents with or without diabetes.
|
31231210 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
The glucagon-like-peptide 1 receptor (GLP-1R) agonists, including liraglutide, can ameliorate neurodegenerative features in models of Alzheimer's disease and diabetes by decreasing tau hyperphosphorylation in the brain.
|
31015047 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Fasting GLP-1 was measured on hospital day 2-4 in patients without previously known diabetes (n = 59) that received recombinant tissue plasminogen activator (rtPA) for ischemic stroke.
|
31307484 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Being a relatively newer class of drug with numerous benefits, several national and international guidelines are working towards addressing clinical questions pertaining to the optimal use of GLP-1 RAs for the management of diabetes.
|
31359367 |
2019 |
|
Diabetes Mellitus
|
0.300 |
Biomarker
|
group |
BEFREE |
Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?
|
31725337 |
2019 |